2024
Is There an Association Between Endometriosis, Early Menopause, and Cardiovascular Disease?
Younis J, Taylor H. Is There an Association Between Endometriosis, Early Menopause, and Cardiovascular Disease? The Journal Of Clinical Endocrinology & Metabolism 2024, 109: e1946-e1949. PMID: 39083665, DOI: 10.1210/clinem/dgae508.Peer-Reviewed Original ResearchEarly menopauseEndometriotic cystectomyNatural menopauseCardiovascular riskCardiovascular diseaseEndometriosis-associated pelvic painIncreased risk of cardiovascular diseaseLaparoscopically diagnosed endometriosisRisk of cardiovascular diseaseEarly natural menopauseLarge-scale cohort studyPelvic painOvarian reserveBilateral casesMenopause onsetMultiple surgeriesEndometriosisCohort studyHazard ratioIncreased riskMenopauseCystectomyRisk factorsEstimates of associationConfounding factorsMedical Management of Endometriosis in Adolescent and Young Adult Women: A Review of 91 Cases of Biopsy-Confirmed Endometriosis
Li H, Esencan E, Song Y, Taylor H, Cho Y, Vash-Margita A. Medical Management of Endometriosis in Adolescent and Young Adult Women: A Review of 91 Cases of Biopsy-Confirmed Endometriosis. Journal Of Obstetrics And Gynaecology Canada 2024, 46: 102562. PMID: 38759792, DOI: 10.1016/j.jogc.2024.102562.Peer-Reviewed Original ResearchCombined oral contraceptivesBiopsy-proven endometriosisLNG-IUDManagement of endometriosisOral progestinInitial treatmentRetrospective chart review of womenChart review of womenMedical management of endometriosisProgestin-only formulationsLevonorgestrel intrauterine deviceReview of womenRetrospective chart reviewYoung adult patientsTertiary hospital systemPelvic painIntrauterine deviceOral contraceptivesTreatment regimensYounger patientsAdult patientsHormonal managementEndometriosisTreatment planningCurrent treatmentLinzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)
Donnez J, Becker C, Taylor H, Herrera F, Donnez O, Horne A, Paszkowski M, Petraglia F, Renner S, Patel A, Boolell M, Bestel E, Dolmans M. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3). Human Reproduction 2024, 39: 1208-1221. PMID: 38648863, PMCID: PMC11144970, DOI: 10.1093/humrep/deae076.Peer-Reviewed Original ResearchNon-menstrual pelvic painAdd-back therapyEndometriosis-associated painPelvic painMonths of therapyPhase 3 studyGedeon RichterData monitoring boardDaily doseStatistically significant reductionPlacebo groupDouble-blindRoche DiagnosticsTreatment of endometriosis-associated painHormonal add-back therapyRates of hot flushesReduce dysmenorrheaGonadotropin-releasing hormone antagonistRisk of bone lossDATE OF FIRST PATIENT’S ENROLMENT:Overall pelvic painPublished phase 2Hypoestrogenic side effectsMonitoring boardCompared to placeboVilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial
Taylor H, Dong L, Haikonen J, Oppelt P, Tamussino K, Wenzl R, Faustmann T, Groettrup-Wolfers E, Ren X, Seitz C. Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial. F&S Reports 2024, 5: 189-196. PMID: 38983729, PMCID: PMC11228778, DOI: 10.1016/j.xfre.2024.03.002.Peer-Reviewed Original ResearchPelvic painSymptomatic endometriosisTreatment of symptomatic endometriosisEndometriosis-associated pelvic painBaseline to month 3Use of pain medicationAverage pain scoreMonths of treatmentPhase 2b randomized controlled trialAssess treatment effectsOutcome measures Primary outcomesPlacebo recipientsRandomized controlled trialsPain scoresMonth 3Pain medicationIncreased painVilaprisanPlaceboPrimary outcomeEndometriosisToxicity findingsIntervention participantsClinical relevanceBleeding intensity
2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushes